Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel Database Unifies the Knowledge of 100 Years of Drug Research

Published: Friday, November 09, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
More than 5000 scientific publications on clinical trials in humans and preclinical animal trials concerning the bioavailability of drugs have been evaluated.

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs.

Several factors affect the oral bioavailability of drugs. For the first time, these can now be analyzed in detail, thanks to a new resource.

The new resource, called PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) unifies the results and experiences of the last hundred years of drug research.

The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database.

Each of the 8296 records contains the chemical structure of the investigated drug and up to 17 additional fields, which describe in detail the experimental conditions of the trials (gender, age, health status and number of subjects, genetic differences, the species examined, route of administration, additional medication, method of measurement, drug formulation and further descriptions of the studies).

The knowledge base is a fundamental tool to develop computer models, which can predict the oral bioavailability of new drugs in humans, before clinical trials have to be conducted.

This increases the prospects of new drugs and enhances the safety of clinical trials in humans.

Dr Wolfgang Boomgaarden, founder and CEO of PharmaInformatic, says, 'Our research is a huge step forward in the area of drug development and will improve the efficiency of clinical trials in humans. Fundamental new findings and conclusions can be derived from the knowledge base which will impact future drug discovery and development.'

Oral bioavailability is one of the most important properties of a drug.

If a new drug candidate has low or no oral bioavailability, further drug development will be stopped, because the candidate cannot be absorbed in the body.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Friday, September 12, 2014
Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!